参一胶囊联合新辅助化疗对进展期食管癌患者手术风险及预后的影响

摘要

目的：探讨参一胶囊联合新辅助化学治疗(简称化疗)对进展期食管癌患者手术风险及预后的影响。方法选择医院普外科2012年1月至2014年1月收治的进展期食管癌患者207例，随机分为治疗组99例和对照组108例。两组患者均接受术前食管癌紫杉醇、顺铂方案﹢根治手术治疗﹢术后紫杉醇、顺铂化疗方案，治疗组患者加用参一胶囊，所有患者均给予对症支持治疗。比较两组患者治疗后的手术情况、治疗有效性、复发率、生存率，记录化疗不良反应并进行安全性分析。结果与对照组比较，治疗组手术情况、治疗有效性较好（ P﹤0.05），复发率较低（ P﹤0.05），3年生存率较高（ P﹤0.05），化疗不良反应发生率较低（ P﹤0.05）。结论参一胶囊联合常规新辅助化疗治疗进展期食管癌，能提高临床疗效和患者远期的生存率，改善围手术期情况，降低化疗不良反应，值得临床推广。%Objective To investigate the influence of Shenyi Capsule combined with the neoadjuvant chemotherapy on the operative risk and prognosis in the patients with the progressive stage of esophageal carcinoma. Methods Totally 207 patients with the progressive stage of esophageal carcinoma treated in the general department of the hospital from January 2012 to January 2014 were selected and randomly divided into the observation group(99 cases) and the control group(108 cases). The patients of the two groups received the preoperative chemotherapeutic regimen of paclitaxel and cisplatinum ﹢ radical operation ﹢ paclitaxel and cisplatinum regimen after postoperative chemotherapy,while the patients in the treatment group was added with Shenyi Capsule. All the patients were given the symptomatic support treatment. The differences in the operation situation,effectiveness of treatment,recurrence rate and survival rate were compared between the two groups. The occurrence situation of adverse reactions was recorded and the safety analysis was per-formed. Results Compare with the contorl group,the operation situation and treatment effectiveness in the treatment group were signifi-cantly better( P ﹤ 0. 05 ),the recurrence rate was significantly lower( P﹤ 0. 05 ),the 3-year survival rate was significantly higher ( P ﹤ 0. 05) and the occurrence rate of chemotherapeutic adverse reactions was significantly lower ( P ﹤ 0. 05 ) . Conclusion Shenyi Capsule combined with the routine chemotherapy for treating the progressive stage of esophageal carcinoma can increase the clinical cu-rative effect and the long term survival rate,improve the perioperative situation,reduce the occurrence rate of chemotherapeutic drugs and is worthy of clinical promotion.